Related Experiment Video

Updated: May 28, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic

Peter Schmid1, Cynthia X Ma2, Yeon Hee Park3

  • 1Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|May 26, 2026
PubMed
Abstract

Insights

First-line durvalumab plus paclitaxel showed clinical activity in triple-negative breast cancer (TNBC). Adding capivasertib or oleclumab did not significantly improve outcomes, though PD-L1 expression correlated with better responses.

Area of Science:

  • Oncology
  • Immunotherapy
  • Breast Cancer Research

Background:

  • Triple-negative breast cancer (TNBC) presents a significant clinical challenge due to its heterogeneity, high recurrence rates, and poor prognosis.
  • Current treatment paradigms for locally advanced unresectable or metastatic TNBC (mTNBC) often involve multiple lines of therapy.

Purpose of the Study:

  • To evaluate the safety and efficacy of first-line treatment combinations involving durvalumab (anti-PD-L1 antibody) in patients with locally advanced unresectable or mTNBC.
  • To assess durvalumab plus paclitaxel, with or without capivasertib (pan-AKT inhibitor) or oleclumab (anti-CD73 antibody).

Main Methods:

  • Phase Ib/II, multiarm, platform study (BEGONIA; NCT03742102) including eligible female participants (≥18 years) with untreated, unresectable, locally advanced/mTNBC.
  • Primary objective: safety and tolerability. Secondary endpoint: objective response rate (ORR).

Main Results:

  • Twenty-three patients received durvalumab plus paclitaxel; 31 received the capivasertib combination; 33 received the oleclumab combination.
  • Grade 3/4 adverse events occurred in 43.5%, 80.6%, and 24.2% of patients, respectively.
  • Confirmed ORRs were 56.5%, 54.8%, and 51.5%, with responses observed across biomarker subgroups.

Conclusions:

  • Durvalumab plus paclitaxel demonstrated clinical activity and tolerability in locally advanced unresectable/mTNBC.
  • Addition of capivasertib or oleclumab did not provide substantial additional benefit.
  • PD-L1 expression was associated with enhanced antitumor activity across all treatment arms.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...